High Throughput Screening (HTS) Market by Technology, Applications, and End Users - Forecast to 2018
The label-free technology market is expected to grow at the highest CAGR of 11.1% from 2013 to 2018. This technology offers the direct detection ability, which was not possible with cell-based assays. Moreover, this technology helps in the reduction of drug failure rate due to toxicity and is applicable for a majority of drug classes.
In the HTS applications market, the target identification segment accounted for the largest share in 2013. The large share of this segment can be attributed to factors such as the availability of large compound libraries, presence of well-equipped HTS laboratories, and technological advancements. Large pharmaceutical and biotechnology companies are investing heavily in automation of HTS laboratories and are also entering into strategic partnerships and collaborations with research institutes, thereby leading to efficient utilization of HTS in varied application fields. However, the primary screening segment of the HTS market is estimated to register the highest growth rate. This can be attributed to the availability of a large number of potential lead compounds, emergence of several new detection technologies, and availability of novel primary and stem cell phenotypes. The HTS market by end users is broadly categorized into pharmaceutical companies, biotechnology companies, academic and government institutes, contract research organizations (CROs), and others. The pharmaceuticals segment dominated the market with a market share of around 48% in 2013.